摘要
目的观察奥曲肽联合乌司他丁治疗重症胰腺炎患者的临床疗效及其安全性。方法选取2020年12月—2021年7月达州市中西医结合医院收治的重症胰腺炎患者80例,按照计算机随机分组法分为对照组与研究组,每组40例。对照组予以乌司他丁,研究组在对照组基础上予以奥曲肽,2组均持续治疗14 d。比较2组胃肠功能恢复时间、体征恢复时间、住院时间,治疗前后血液指标[血红蛋白(Hb)与白蛋白(Alb)]、血清酶指标[淀粉酶(AMS)、脂肪酶(LPS)]、炎性反应指标[白细胞计数(WBC)、C反应蛋白(CRP)及降钙素原(PCT)]及不良反应。结果研究组胃肠功能恢复时间、体征恢复时间、住院时间短于对照组(P<0.01)。治疗后,2组Hb、Alb高于治疗前,AMS、LPS低于治疗前,且研究组Hb、Alb高于对照组,AMS、LPS低于对照组(P<0.01)。治疗后,2组WBC、CRP、PCT低于治疗前,且研究组低于对照组(P<0.01)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论奥曲肽联合乌司他丁治疗重症胰腺炎患者可缩短胃肠功能及体征恢复时间和住院时间,降低血清AMS、LPS水平,减轻炎性反应,且安全性较高。
Objective To observe the clinical efficacy and safety of octreotide combined with ulinastatin in the treatment of severe pancreatitis.Methods A total of 80 cases of patients with severe pancreatitis were selected from December 2020 to July 2021 in Dazhou Hospital of Integrated Traditional Chinese and Western Medicine,which were divided into control group and study group according to computer random grouping method,with 40 cases in each group.The control group was given ulinastatin,while the study group was given octreotide on the basis of the control group.Both groups were treated for 14 days.Recovery time of gastrointestinal function,recovery time of signs,hospital stay,blood indexes(Hb and Alb),serum enzyme indexes(AMS and LPS),inflammatory reaction indexes(WBC,CRP and PCT)before and after treatment,and incidence of adverse reactions were compared between the two groups.Results The recovery time of gastrointestinal function,signs and hospital stay in the study group were shorter than those in the control group(P<0.01).After treatment,Hb and Alb in the two groups were higher than those before treatment,AMS and LPS were lower than those before treatment,and Hb and Alb in the study group were higher than those in the control group,while AMS and LPS were lower than those in the control group(P<0.01).After treatment,WBC,CRP and PCT in the two groups were lower than those before treatment,and those in the study group were lower than the control group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Octreotide combined with ulinastatin can shorten the recovery time of gastrointestinal function and signs and hospitalization time of patients with severe pancreatitis,reduce the serum levels of AMS and LPS,reduce the inflammatory reaction,and with high safety.
作者
周殿耀
李林敏
ZHOU Dianyao;LI Linmin(Department of Critical Care Medicine,Dazhou Hospital of Integrated Traditional Chinese and Western Medicine,Dazhou 635000,China)
出处
《临床合理用药杂志》
2022年第15期30-32,39,共4页
Chinese Journal of Clinical Rational Drug Use
